Soligenix Inc
NASDAQ:SNGX

Watchlist Manager
Soligenix Inc Logo
Soligenix Inc
NASDAQ:SNGX
Watchlist
Price: 1.43 USD 0.7% Market Closed
Market Cap: 14.4m USD

Soligenix Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Soligenix Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Soligenix Inc
NASDAQ:SNGX
Operating Income
-$12.4m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
-6%
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Soligenix Inc
Glance View

Market Cap
14.1m USD
Industry
Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The firm is focused on developing products to treat rare diseases. The firm operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of HyBryte (SGX301 or synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions segment includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The firm's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203).

SNGX Intrinsic Value
Not Available

See Also

What is Soligenix Inc's Operating Income?
Operating Income
-12.4m USD

Based on the financial report for Sep 30, 2025, Soligenix Inc's Operating Income amounts to -12.4m USD.

What is Soligenix Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-6%

Over the last year, the Operating Income growth was -57%. The average annual Operating Income growth rates for Soligenix Inc have been 7% over the past three years , 5% over the past five years , and -6% over the past ten years .

Back to Top